GlobeNewswire: AXIM BIOTECHNOLOGIES, INC Contains the last 10 of 184 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T13:17:42ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/12/13/2572836/0/en/AXIM-Biotechnologies-Develops-Novel-Dual-IgE-MMP-9-Rapid-Ophthalmological-Diagnostic-Test-Files-Provisional-Patent.html?f=22&fvtc=4&fvtv=23948AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent2022-12-13T14:00:00Z<![CDATA[Leading Diagnostic Healthcare Company Announces Development of and Provisional Patent Filing on First-of-Its-Kind Point-of-Care Ophthalmological Diagnostic Solution Enabling Precision Treatment of Common Eye Conditions Leading Diagnostic Healthcare Company Announces Development of and Provisional Patent Filing on First-of-Its-Kind Point-of-Care Ophthalmological Diagnostic Solution Enabling Precision Treatment of Common Eye Conditions]]>https://www.globenewswire.com/news-release/2022/12/06/2568388/0/en/AXIM-Biotechnologies-Commercial-Partner-Vers%C3%A9a-Ophthalmics-Highlights-Benefits-of-AXIM-s-Eye-Diagnostic-Solutions.html?f=22&fvtc=4&fvtv=23948AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic Solutions2022-12-06T14:00:00Z<![CDATA[Technology and Benefits Company At Forefront of Leading Ophthalmological Media Outlets’ Coverage of Innovative Diagnostic Solutions Technology and Benefits Company At Forefront of Leading Ophthalmological Media Outlets’ Coverage of Innovative Diagnostic Solutions]]>https://www.globenewswire.com/news-release/2022/10/04/2527882/0/en/AXIM-Biotechnologies-Receives-Initial-Order-for-Diagnostic-Solutions-as-Exclusive-Partner-Vers%C3%A9a-Ophthalmics-Commences-Initial-Commercial-Launch.html?f=22&fvtc=4&fvtv=23948AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch2022-10-04T13:00:00Z<![CDATA[Healthcare Solutions Company Receives Initial Order for Ophthalmic Diagnostic Tests and Readers, Marking First Large Revenue Generating Order for Company Healthcare Solutions Company Receives Initial Order for Ophthalmic Diagnostic Tests and Readers, Marking First Large Revenue Generating Order for Company]]>https://www.globenewswire.com/news-release/2022/09/29/2525109/0/en/AXIM-Biotechnologies-Point-of-Care-Diagnostic-Test-Platform-Sales-Commence-With-Vers%C3%A9a-Ophthalmics-Commercial-Launch-at-AAO-2022.html?f=22&fvtc=4&fvtv=23948AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics’ Commercial Launch at AAO 20222022-09-29T12:00:00Z<![CDATA[Sales of Point-of-Care Diagnostic Tests for Ocular Surface Disease Commence at the American Academy of Ophthalmology Annual Meeting Through Exclusive Partnership Sales of Point-of-Care Diagnostic Tests for Ocular Surface Disease Commence at the American Academy of Ophthalmology Annual Meeting Through Exclusive Partnership]]>https://www.globenewswire.com/news-release/2022/09/19/2518386/0/en/AXIM-Biotechnologies-Signs-Exclusive-Global-Commercialization-Agreement-With-Vers%C3%A9a-Ophthalmics-for-Distribution-and-Sales-of-Novel-Ophthalmic-Diagnostics-Solutions.html?f=22&fvtc=4&fvtv=23948AXIM® Biotechnologies Signs Exclusive Global Commercialization Agreement With Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions2022-09-19T13:00:00Z<![CDATA[Under the Agreement the Company will Sell and Distribute Globally AXIM’s Readers and Three Novel Proprietary Tests Designed for Diagnosis of Dry Eye Disease Under the Agreement the Company will Sell and Distribute Globally AXIM’s Readers and Three Novel Proprietary Tests Designed for Diagnosis of Dry Eye Disease]]>https://www.globenewswire.com/news-release/2022/07/26/2486010/0/en/AXIM-Biotechnologies-Enhances-IgE-Testing-Capabilities-Responds-to-Global-Warming-s-Impact-on-Allergy-Season.html?f=22&fvtc=4&fvtv=23948AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season2022-07-26T13:00:00Z<![CDATA[SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has launched an enhanced version of its rapid Ocular Immunoglobulin E (IgE) test in response to a study recently published in Nature by researchers at the University of Michigan Department of Climate and Space Sciences and Engineering.]]>https://www.globenewswire.com/news-release/2022/07/21/2483708/0/en/AXIM-Biotechnologies-Celebrates-Feature-on-the-Vision-is-More-Than-20-20-Podcast.html?f=22&fvtc=4&fvtv=23948AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast2022-07-21T13:00:00Z<![CDATA[SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that its CEO John Huemoeller has been featured on the Vision is More Than 20/20™ podcast.]]>https://www.globenewswire.com/news-release/2022/07/12/2478178/0/en/AXIM-Biotechnologies-Publishes-Study-Highlighting-Neutralizing-Antibody-Levels-of-Poor-Vaccine-Responders-with-a-Third-COVID-19-Vaccine-Dose.html?f=22&fvtc=4&fvtv=23948AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose2022-07-12T13:00:00Z<![CDATA[SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their publication in collaboration with researchers at Arizona State University (ASU) entitled, “Third COVID-19 Vaccine Dose Boosts Neutralizing Antibodies in Poor Responders” in Communications Medicine, part of the Nature family of journals.]]>https://www.globenewswire.com/news-release/2022/06/02/2455281/0/en/AXIM-Launches-New-Eye-Care-Website-Establishes-Platform-for-Commercialization.html?f=22&fvtc=4&fvtv=23948AXIM Launches New Eye Care Website; Establishes Platform for Commercialization2022-06-02T13:00:00Z<![CDATA[SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, today announced the launch of its new mobile-optimized website designed to provide doctors, researchers and other medical professionals with tailored, timely information and resources that will enable them to make informed decisions when purchasing AXIM’s proprietary diagnostic tests.]]>https://www.globenewswire.com/news-release/2022/05/24/2449460/0/en/AXIM-Biotechnologies-Completes-Optimization-of-Only-FDA-Cleared-IgE-Rapid-Diagnostics-Test-In-House-Manufacturing-Lowers-Cost-and-Eliminates-Supply-Chain-Expenditures.html?f=22&fvtc=4&fvtv=23948AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures 2022-05-24T13:00:00Z<![CDATA[SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases announced today that its scientific team has completed the optimization of a rapid diagnostics test for the quantitative measurement of Ocular Immunoglobulin E (IgE), a biomarker for ocular allergies. The test is a simple, rapid, and non-invasive immuno-chromatographic test that enables the identification of allergic conjunctivitis in one single step.]]>